A surge in cross-border pharmaceutical transactions has placed China’s drug development sector at the center of a record-setting first half of 2026, with deal values reaching US$110 billion by June 30. Now, according to a senior Chinese regulator and recent industry moves, artificial intelligence is emerging as the next driver of growth, signaling a shift in how new medicines are discovered and traded globally.
Speaking at a forum over the weekend, Lan Gongtao, deputy director general of the Department of Drug Registration at China’s National Medical Products Administration, confirmed that the country now accounts for roughly 30% of all new drugs currently under development worldwide, securing the second-highest global ranking. Lan characterized China’s pharmaceutical industry as having ascended to the top tier globally in innovation efficiency. His remarks, reported by Chinese state media Monday, come as the sector closes a six-month period that already rivals the annual totals of just a year earlier.
Record-Breaking First-Half Deal Flow
Between January 1 and June 30, 2026, 81 cross-border deals for innovative drugs were finalized, according to official accounts. That number equates to about 80% of the full-year total achieved in 2025, underscoring a steep acceleration in transaction activity.
These agreements spanned 10 distinct therapeutic areas, including oncology, metabolic diseases, immunology, and neurology—fields that reflect the most urgent demands of global pharmaceutical markets. The buyers involved in these 81 deals hailed from 20 countries and regions, with the United States, the United Kingdom, France, and Italy identified as the primary sources. This geographic diversity suggests that international confidence in China’s drug development pipeline remains robust, even as competition in high-value therapeutic categories intensifies. The US presence as a leading buyer is particularly notable, given the historical dominance of American and European firms in early-stage drug innovation.
For US-based pharmaceutical companies, Chinese partnerships offer access to a fast-growing pipeline of candidates and, increasingly, to artificial intelligence platforms that promise to shorten discovery timelines.
AI-Driven Collaborations and the Pivot to Machine Learning
The deal-making momentum has carried into July. On July 2, CSPC Pharmaceutical Group announced a new collaboration with AstraZeneca, a major Anglo-Swedish drugmaker.
Under the agreement, the two companies will leverage CSPC’s proprietary AI molecular design platform to jointly discover and develop new drugs. The CSPC-AstraZeneca deal is part of a broader pivot toward AI-powered drug candidates that industry observers say could drive the next wave of cross-border transactions. Rather than relying solely on traditional screening methods, Chinese firms are increasingly embedding machine learning into their research and development operations, aiming to improve the speed and accuracy of identifying viable compounds. Lan’s forum remarks underscored that China’s innovation efficiency has placed its pharmaceutical sector in a position to compete on the global stage.
The emphasis on AI aligns with China’s longer-term industrial transformation. The country’s rapid economic expansion since reforms began in 1978 has reshaped it from an agrarian society into a modern manufacturing and technology powerhouse.
That trajectory now extends into pharmaceuticals, where Chinese firms are not only producing generics but also developing original therapies and—critical for the latest deals—the computational tools to design them. The background of China’s ascent in this sector carries significant implications for the global drug development landscape. The country’s pharmaceutical growth reshapes how new medicines are discovered, developed, and traded across borders, altering competitive dynamics that have long been concentrated in the US and Europe.
For American companies, partnerships such as the one between CSPC and AstraZeneca offer a way to tap into a pipeline that now represents nearly a third of the world’s new drug candidates without building equivalent infrastructure from scratch. With the first half of 2026 already matching 80% of the full-year total for 2025, and July already bringing a major AI-driven collaboration, the second half of the year could see further records broken.
The convergence of high deal volumes, broad therapeutic coverage, and a deliberate shift toward artificial intelligence suggests that China’s pharmaceutical industry is positioning itself as a long-term competitor—and collaborator—in one of the world’s most valuable and strategically important industries.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “China’s Drug Boom: AI Poised to Transform Global Medicine Discovery”, “description”: “BEIJING, July 13 — A surge in cross-border pharmaceutical transactions has placed China’s drug development sector at the center of a record-setting first half of…”, “datePublished”: “2026-07-13T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “James Roberto”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
